Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 2 of 2
Full-Text Articles in Medicine and Health Sciences
Motivations And Barriers To Pursue Cancer Genomic Testing: A Systematic Review, Megan Smith-Uffen, Nicci Bartley, Grace Davies, Megan Best
Motivations And Barriers To Pursue Cancer Genomic Testing: A Systematic Review, Megan Smith-Uffen, Nicci Bartley, Grace Davies, Megan Best
IES Papers and Journal Articles
Objectives: Single-gene testing is associated with psycho-social challenges for cancer patients. Genomic testing may amplify these. The aim of this study was to understand patients’ motivations and barriers to pursue cancer genomic testing, to enable healthcare providers to support their patients throughout the testing process and interpretation of test results.
Methods: Five databases were searched for original peer reviewed research articles published between January 2001 and September 2018 addressing motivation for genomic cancer testing. QualSyst was used to assess quality.
Results: 182 studies were identified and 17 were included for review. Studies were heterogenous. Both somatic and germline testing were …
Longitudinal Patterns In Fear Of Cancer Progression In Patients With Rare, Advanced Cancers Undergoing Comprehensive Tumour Genomic Profiling, Phyllis Butow, Fabiola Müller, Christine E. Napier, Nicci Bartley, Mandy L. Ballinger, Barbara Biesecker, Ilona Juraskova, Bettina Meiser, Timothy E. Schlub, David M. Thomas, David Goldstein, Megan C. Best, Members Of The Pigeon Project
Longitudinal Patterns In Fear Of Cancer Progression In Patients With Rare, Advanced Cancers Undergoing Comprehensive Tumour Genomic Profiling, Phyllis Butow, Fabiola Müller, Christine E. Napier, Nicci Bartley, Mandy L. Ballinger, Barbara Biesecker, Ilona Juraskova, Bettina Meiser, Timothy E. Schlub, David M. Thomas, David Goldstein, Megan C. Best, Members Of The Pigeon Project
IES Papers and Journal Articles
Introduction: Fear of cancer progression (FCP) impacts quality of life and is a prevalent unmet need in patients diagnosed with advanced cancer, particularly as treatment options are reduced. We aimed to identify longitudinal patterns in FCP over 6 months in patients with advanced cancer receiving comprehensive tumour genomic profiling (CTGP) results, and their correlates.
Methods: Patients with pathologically confirmed metastatic disease (∼70% rare cancers) receiving or post their last line of standard therapy completed questionnaires at T0 (prior to CTGP), T1 (immediately post CTGP results) and T2 (2 months later).
Results: High stable (N = 52; 7.3%) and low/moderate …